Abacavir+Lamivudine bulk supplier for pharma manufacturers

Abacavir+Lamivudine 600mg+300mg Suppliers & Bulk Manufacturers

Available Forms: Tablets / Oral solution

Available Strengths: 600mg+300mg

Reference Brands: Epzicom (USA), Kivexa (USA/EU)

Abacavir/Lamivudine is a fixed-dose antiretroviral combination used in the treatment of HIV-1 infection. It combines two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the reverse transcriptase enzyme, preventing viral replication and reducing viral load in patients.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Abacavir+Lamivudine? List it or send an offer →

Product Description:

This tablet combines two nucleoside reverse transcriptase inhibitors. Abacavir is a guanosine analogue and lamivudine a cytidine analogue; both are phosphorylated inside the cell and then incorporated into the growing viral DNA chain, where the missing hydroxyl group stops the chain being extended. Using two drugs from the same class but with different resistance patterns forms the backbone of HIV therapy, to which a third agent from another class is added.

It is used for HIV-1 infection in adults and adolescents, as one tablet once daily. The critical safety point is abacavir hypersensitivity: a systemic reaction with fever, rash, gastrointestinal and respiratory symptoms that can be fatal on rechallenge. It is strongly associated with the HLA-B*5701 allele, and screening for it before the first dose has made the reaction largely avoidable — testing is mandatory in guidelines. Lamivudine is also active against hepatitis B, so stopping it in a co-infected patient can cause a severe hepatitis flare.

Sourcing notes. Off patent, with generics widely available, and a major product in public HIV programmes where tender price decides awards. HLA-B*5701 testing capability in the destination market is a prerequisite for safe use.

Abacavir+Lamivudine — third party manufacturing & bulk supply

Abacavir+Lamivudine 600mg+300mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Abacavir+Lamivudine is supplied as Tablets / Oral solution — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Abacavir+Lamivudine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Abacavir+Lamivudine →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Abacavir and Lamivudine are used together as part of combination antiretroviral therapy for the treatment of HIV-1 infection. This fixed-dose combination helps lower viral load, improve immune function, and reduce the progression of HIV when used with other antiretroviral medicines.

This combination contains two active ingredients: abacavir, a nucleoside reverse transcriptase inhibitor (NRTI) that blocks viral DNA chain elongation, and lamivudine, another NRTI that interferes with viral replication by inhibiting reverse transcriptase. Together, they provide dual NRTI backbone coverage.

The most recognized international trade names for this combination are Kivexa and Epzicom. Several generic brands also exist in different markets.

Kivexa and Epzicom are manufactured by ViiV Healthcare, a joint venture of GSK, Pfizer, and Shionogi.

The generic name of the product is abacavir and lamivudine.

Common brand names include Kivexa and Epzicom, along with various generic versions depending on the region.

Abacavir and Lamivudine combination products (Kivexa/Epzicom) are manufactured by ViiV Healthcare in its approved global facilities. Generic formulations are widely produced in India and other countries by licensed pharmaceutical manufacturers based on regulatory approvals.